4Pauwels RA,Buist AS,Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Am J Respir Crit Care Med,2001,163:1256-1276.
5Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med, 1998,158:1277-1285.
6Zalacain R, Sobradillo V, Amilibia J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J, 1999,13:343-348.
7Sohy C, Pilette C, Niederman MS, et al. Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed. Eur Respir J,2002,19:966-975.
8Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Immunoferon). Am J Repir Crit Care Med,2001,163:1578-1583.
9Monso E,Rosell A,Bonet G,et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J, 1999, 13:338-342.
10Wilkinson TM,Patel IS, Wilks M, et al. Airway Bacterial local and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Repir Crit Care Med,2003,167:1090-1095.
